Abstract Library

#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1821 Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies

Introduction: LAN 120mg has been shown to significantly prolong progression-free survival (PFS) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Phan A

Authors: Phan A, Pavel M, Caplin M, Wolin E, Mirakhur B,

Keywords: lanreotide,

#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Phan A, Wolin E, Fisher G, Ruszniewski P, Pavel M,

Keywords: Lanreotide, safety,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors

Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,